IPD.AX ImpediMed Limited (ASX) down 21.05% on 10 Feb 2026: heavy volume suggests watch for support

IPD.AX stock plunged 21.05% to A$0.015 on 10 Feb 2026 on very heavy trading. The drop followed an open at A$0.019 and a single-day volume of 54,121,941 shares, almost eleven times the average. This move leaves ImpediMed Limited (ASX, Australia) trading near its year low of A$0.015. Investors should weigh weak profitability and high volatility against the company’s BIS device portfolio and cash buffers.

IPD.AX stock today: price action and volume

IPD.AX stock closed at A$0.015, down 21.05% from the previous close of A$0.019. Volume spiked to 54,121,941, versus an average volume of 4,749,475, giving a relative volume of 10.99. The day high was A$0.019 and the day low A$0.015. The price now sits below the 50-day average of A$0.0326 and the 200-day average of A$0.03721, signalling strong selling pressure.

IPD.AX stock fundamentals and valuation

ImpediMed Limited (IPD.AX) operates in Healthcare, Medical – Devices, selling BIS devices like SOZO. Revenue per share is A$0.00630 and EPS is -A$0.01, producing a trailing PE of -1.50. Price to sales is 2.40 and price to book is 1.48. Market cap is approximately A$30,581,214 with 2,038,747,620 shares outstanding. The company shows a strong current ratio of 4.86, but negative operating cash flow per share of -A$0.00754, highlighting cash burn risks.

Technical outlook for IPD.AX stock

Technically, the stock lacks a clear trend. RSI is 45.33, ADX is 12.11, and Bollinger middle band sits near A$0.04. The stock is below key moving averages. Short-term support is the year low at A$0.015 and resistance near the 50-day average of A$0.0326. Analysts note wide intraday ranges and low liquidity at current levels, increasing volatility for small trades.

Meyka AI rates IPD.AX with a score out of 100

Meyka AI rates IPD.AX with a score out of 100: 66.29 / 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s product set and a positive current ratio lift the score. Weak earnings and persistent losses limit the rating. These grades are not guaranteed and we are not financial advisors.

Meyka AI’s forecast model projects short-term targets

Meyka AI’s forecast model projects a monthly price of A$0.01 and a quarterly price of A$0.02. Versus the current A$0.015, the monthly projection implies -33.33% downside and the quarterly projection implies +33.33% upside. Forecasts are model-based projections and not guarantees. Use forecasts alongside company updates and earnings scheduled for 20 Feb 2026.

Risks, catalysts and sector context for IPD.AX stock

Key risks include ongoing negative earnings, thin trading at low prices, and sector valuation gaps. The Healthcare sector average PE is 32.54, while IPD.AX shows a negative PE. Catalysts that could stabilise the stock include stronger SOZO sales, veterinary device uptake, or positive trial results. Watch upcoming earnings and any commercial contract announcements closely.

Final Thoughts

IPD.AX stock closed the ASX session at A$0.015 on 10 Feb 2026 after a 21.05% fall on record volume. The move reflects market concern about profitability and liquidity despite a solid current ratio of 4.86. Technicals show the stock below both the 50-day average (A$0.0326) and the 200-day average (A$0.03721). Meyka AI’s models give mixed near-term signals: a monthly projection of A$0.01 (-33.33% vs today) and a quarterly projection of A$0.02 (+33.33% vs today). Our price targets frame a base downside near A$0.01 and a recovery target of A$0.03 if revenue momentum returns. Traders should treat IPD.AX as high risk and size positions carefully. Use upcoming earnings on 20 Feb 2026 and any commercial updates to reassess risk. Meyka AI provides this as AI-powered market analysis and not personal financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.